In­ter­nal doc­u­ments shed new light on Sarep­ta FDA de­ci­sion, which top agency of­fi­cial says was ‘ex­cep­tion­al’

While he has re­peat­ed­ly ad­vo­cat­ed for ac­cel­er­at­ed gene ther­a­py ap­provals, the FDA’s top cell and gene ther­a­py of­fi­cial Pe­ter Marks said that the agency’s land­mark …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER